CareQuest Institute Raises Alarm Over Medicaid Cuts That Threaten Dental Access
CareQuest Institute Senior Director of Public Policy Melissa Burroughs issued the following statement:
'The passage of this legislation marks a dangerous setback for Medicaid and the millions of people who rely on it for essential health care, which includes oral health. Deep cuts to Medicaid funding, new work requirements, and caps on the mechanisms that states use to fund the program threaten to drastically reduce access to care across the country.
"This bill will make it harder for millions of families to afford dental care, for adults to manage chronic conditions tied to oral health, and for children and families in rural and low-income areas to find providers who can accept Medicaid or keep their doors open at all. History tells us that when states are forced to cut dental benefits, the damage can take years to undo–and often results in higher costs and overcrowded emergency rooms.
"At a time when we should be improving access to prevention and care, this bill moves in the wrong direction. We urge Congress to prioritize policies that protect and strengthen access to oral health care–not dismantle it.'
About CareQuest Institute for Oral Health ®
CareQuest Institute for Oral Health® is a national nonprofit championing a more equitable future where every person can reach their full potential through excellent health. We do this through our work in philanthropy, analytics and data insights, health transformation, policy and advocacy, and education as well as our leadership in dental benefits and innovation advancements. We collaborate with thought leaders, health care providers, patients, and local, state, and federal stakeholders, to accelerate oral health care transformation and create a system designed for everyone. To learn more, visit carequest.org and follow us on Twitter, LinkedIn, Facebook, and Instagram.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
MedX Health Corp. Names Meghan Geary as Senior Vice President of Operations
MISSISSAUGA, Ontario--(BUSINESS WIRE)--MedX Health Corp. ('MedX' or the 'Company') (TSXV: MDX), the global leader in teledermatology solutions, confirms the appointment of Meghan Geary as the Company's Senior Vice President of Operations, effective immediately. With over 10 years experience in building scalable programs across SaaS and high-growth healthcare companies, Geary will oversee strategic operations, drive organization performance, and support MedX's continued growth trajectory. "I'm excited to join MedX at such a pivotal stage of its journey," said Geary. "Throughout my career, I've focused on scaling programs that streamline processes and promote cross-functional alignment. I look forward to collaborating with the MedX team to optimize operations and ensure the Company is positioned for long-term success." The Company's CEO, John Gevisser added: 'Meghan brings formidable experience to MedX at a time when we are scaling operations across different markets. Having previously worked closely with her, I understand what a vital asset to our team she is. Her ability to lead strategic programs, adjust and direct processes and improve organizational performance will play a central role in our next phase of growth. Meghan critically understands that our deep and dynamic image store is central to our AI and SaaS strategy.' About MedX Health Corp. MedX Health Corp., headquartered in Ontario, Canada, is a leader in non-invasive skin assessment and teledermatology. Its proprietary SIAscopy ® technology, integrated into the DermSecure ® platform, enables pain-free, accurate imaging of skin lesions for rapid dermatologist review. These products are cleared for use in 38 countries including by Health Canada, the U.S. Food and Drug Administration ('FDA'), the Therapeutic Goods Administration and Conformité Européenne, for use in Canada, the U.S., Australia, New Zealand, the United Kingdom, the European Union and Turkey. MedX's advanced telemedicine platform enables healthcare professionals to quickly and accurately assess suspicious moles, lesions, and other skin conditions through its proprietary imaging technology, SIAscopy ®, and its secure, cloud-based patient management system, DermSecure ®. SIAscopy® is the only technology capable of capturing five high-resolution images, including four spectrophotometric scans that penetrate 2mm below the skin's surface. Visit: https// This Media Release may contain forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties.
Business Wire
2 hours ago
- Business Wire
Modivcare Enters into Comprehensive Restructuring Agreement to Strengthen its Future, Reduce Debt and Inject Capital
DENVER--(BUSINESS WIRE)--Modivcare Inc. (the 'Company' or 'Modivcare') (Nasdaq: MODV), a technology-enabled healthcare services company providing a platform of integrated supportive care solutions focused on improving health outcomes, today announced that it has taken necessary and decisive action intended to strengthen its financial foundation while continuing to provide access to care, reduce costs, and improve outcomes for clients and members nationwide. Modivcare has filed for voluntary Chapter 11 protection in the U.S. Bankruptcy Court for the Southern District of Texas to implement a comprehensive restructuring transaction with the support of a supermajority of its key stakeholders. Through this process, Modivcare intends to build a stronger, sustainable organization, positioned for growth and well-equipped to meet the critical needs of members across its non-emergency medical transportation, personal care services and remote patient monitoring service lines. 'Modivcare sits at the center of the preventive healthcare ecosystem,' said Heath Sampson, Chief Executive Officer and President of Modivcare. 'This recapitalization strengthens our balance sheet and allows Modivcare to accelerate our investment in innovation by combining technology and data with high-touch member engagement. As the connector to care, our seamlessly connected platform improves access, quality and cost for payors, providers and facilities, while positioning us to lead the future of coordinated care.' More than 90% of First Lien Lenders and more than 70% of Second Lien Lenders have entered into a Restructuring Support Agreement ('RSA') with the Company. Those lenders have committed to support the Company throughout this process and have agreed to provide $100 million in 'debtor-in-possession' ('DIP') financing to finance the restructuring process and to support ongoing operations during this expedited bankruptcy process. Upon the closing of the DIP loan, Modivcare will have liquidity in excess of $100 million. The restructuring will reduce the Company's total outstanding funded debt obligations by approximately $1.1 billion (which is more than 85% of its outstanding funded debt obligations) and will meaningfully reduce the Company's annual cash interest and transition ownership to a group of seasoned and well-funded investors who are committed to Modivcare's success. All of Modivcare's service lines will continue to operate in the ordinary course, and we expect no interruption or change in access to care and a continued focus on operational excellence. Modivcare intends to close this transaction quickly by exiting the restructuring process early in the fourth quarter of 2025. Modivcare remains committed to providing excellent service to clients and their members. The Company has filed customary motions that, once approved, will allow Modivcare to meet obligations to clients and critical vendors, including transportation providers, and pay employee wages and benefits as usual. For more information about the Company's Chapter 11 case, including claims information, please visit or contact Verita, the Company's noticing and claims agent, at +1 (888) 733-1521 for U.S. and Canada or +1 (310) 751-2636 for international. Modivcare is advised by Latham & Watkins LLP, Hunton Andrews Kurth LLP, Moelis & Company LLC, and FTI Consulting. The First Lien Agent, the First Lien Lenders and the Second Lien Noteholders executing the RSA are advised by Paul Hastings LLP and Lazard. Cautionary Note Regarding Forward-Looking Statements Statements contained in this release constitute 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are predictive in nature and are identified generally by the use of the terms 'intended', 'expected', 'estimates', 'will', and 'anticipates', and similar words or expressions indicating possible future expectations, events or actions. Forward-looking statements include statements regarding the Company's expectation about its ability to continue operating its business, fulfill its mission, make payments and meet obligations, and the Company's ability to implement the restructuring pursuant to the Chapter 11 cases, including the timetable of completing such transaction, if at all. Forward-looking statements are based on current expectations, assumptions, estimates and projections about the Company's business and its industry, and are not guarantees of future performance. These statements are subject to a number of known and unknown risks, uncertainties and other factors, many of which are beyond the Company's ability to control or predict, which may cause actual events to be materially different from those expressed or implied herein. The Company has provided additional information about the risks facing its business and the Company in its most recent annual report on Form 10-K, and in its subsequent periodic and current reports on Forms 10-Q and 8-K, filed by it with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date the statements were made and are expressly qualified in their entirety by the cautionary statements set forth herein and in the periodic and current reports filed with the Securities and Exchange Commission identified above, which you should read in their entirety before making an investment decision with respect to the Company's securities. The Company undertakes no obligation to update or revise any forward-looking statements contained in this report, whether as a result of new information, future events or otherwise, except as required by applicable law. About Modivcare Modivcare Inc. ("Modivcare" or the "Company") is a technology-enabled healthcare services company that provides a suite of integrated supportive care solutions for public and private payors and their members. The Company's value-based solutions address the social determinants of health (SDoH) by connecting members to essential care services. By doing so, Modivcare helps health plans manage risks, reduce costs, and improve health outcomes. Modivcare is a provider of non-emergency medical transportation (NEMT), personal care services (PCS), and remote patient monitoring solutions (RPM). To learn more about Modivcare, please visit
Medscape
4 hours ago
- Medscape
Vaccine-Preventable Disease: Could the Sky Fall?
It's been a tempestuous 2025 for the nation's healthcare infrastructure. I think the worst is yet to come, given cutbacks to Medicaid eligibility and coverage and the devolving recommendations by government healthcare agencies. Concern is also arising that third-party payers (Medicaid, Medicare, and private insurance) and Vaccines for Children may not cover some scientifically proven vaccines or some parts of scientifically based schedules. Vaccination rates and public trust in vaccines had been dropping since the pandemic, and only 69% of families trusted CDC vaccine recommendations in January 2025, even before recent shakeups in CDC committees. Declining postpandemic national vaccine rates now hover just above thresholds for losing herd immunity (Figure 1) also in part because of increasing vaccine exemptions (Figure 2). However, some local rates have dipped below thresholds in what I call 'vaccine deserts,' those geographic pockets where vaccine deniers comprise larger parts of the population — the measles outbreak being the poster child for this. In addition, discussions are emerging about limiting or removing school vaccine requirements or expanding exemptions. Other factors that imperil herd immunity have always reduced vaccine uptake, even in families that want to vaccinate their children: time and resource limitations for working parents, language barriers, limited or no medical care coverage, limited transportation, rural or inner-city residence, and uncovered vaccines. Some may say, 'So what?' We still have more than 90% uptake for most vaccines. Evidence suggests that even with relatively high uptake, vaccine-preventable disease still occurs in subpopulations, including vulnerable children. For example, a Boston group recently reported that, even before the drop in vaccination rates over the past 5 years, vulnerable children were more likely have more invasive pneumococcal disease (IPD). So, cracks in the proverbial dam existed in populations (those with comorbidities or lower socioeconomic status) even pre-pandemic and before current cutbacks. Massachusetts IPD data (ie, Optum Clinformatics DataMart and Merative MarketScan Medicaid Multi-State Database) from a time of Medicaid expansion (January 2015 through December 2019) were analyzed by insurance type and comorbidities. As expected, children younger than 2 years and particularly those younger than 1 year had the highest IPD rates regardless of insurance status, but children with Medicaid had higher IPD rates than commercially insured children. Of concern, these differences occurred despite statewide pneumococcal conjugate vaccine vaccination rates reported previously as being fairly high (92% with three or more doses by 2 years of age). Relative IPD rates for children with Medicaid vs those with commercial insurance were higher in infants (1.3, 95% CI, 0.9-1.9) and adolescents (3.4, 95% CI, 1.5-7.1). Among children with comorbidities, the IPD rate was about four times higher in infants and 10 times higher in 6- to 10-year-olds, regardless of insurance type. The authors cite three prior studies showing lower vaccine uptake in Medicaid recipients, suggesting that, among factors affecting Medicaid patients' IPD burden, lower vaccine uptake likely has a role. It seems logical that these prepandemic, pre-cutback data foreshadow darker times ahead due to a combination of increasing postpandemic public distrust, vaccine fatigue, and cutback-era policies. Not only is vaccine confidence still dropping and Medicaid becoming more restrictive at the federal level, but states may change Medicaid coverage when more costs are reassigned to them. The bottom line is that vaccine availability and access will likely decrease, even in non-economically vulnerable children. So, all children could be exposed to increased types of circulating infectious disease — resulting in increased IPD, particularly in vulnerable children. And here we are only considering one among many vaccine-preventable diseases. As pediatric providers, can we close the anticipated vaccine gaps as vulnerable families deal with healthcare cutbacks and likely become more economically vulnerable? One way is to rededicate ourselves to getting as many children as possible vaccinated (eg, reminder texts, emails, phone calls before vaccine due dates) according to schedules recommended by organizations that are politically independent and science-driven, such as the American Academy of Pediatrics, the American Academy of Family Physicians, and the American College of Obstetricians and Gynecologists. It's not a time for 'business as usual.' We need to proactively confirm our belief in scientifically based vaccine schedules to the families of our patients. While I strongly believe in patient medical homes, there may be room for flexibility if vaccines become available from alternative sources that are economically helpful to families. We can hope charitable organizations, foundations, and some altruistic individuals will ramp up funding to fill the evolving voids. The answers are not simple nor are potential fixes easy. Yet, pediatric providers have always answered the call when children are in jeopardy. Let's keep as many children safe as possible.
